Introduction

• The Global Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents and Dialysate Solutions Market was valued at USD 4,956.77 million in 2025 and is projected to reach USD 10,411.84 million by 2036, growing at a CAGR of 6.98% from 2025 to 2036. Market growth is supported by rising chronic kidney disease burden, increasing preference for home-based renal care, and the need for safer long-term PD fluid options.
• The market is gaining importance as healthcare providers look beyond conventional glucose-based PD solutions due to concerns related to glucose exposure, metabolic stress, fluid imbalance, and long-term peritoneal membrane damage. Non-glucose osmotic agents such as icodextrin and amino acid-based solutions are increasingly positioned as value-added options for improving ultrafiltration, supporting nutritional needs, and enhancing treatment flexibility in selected PD patients.
• Innovation in biocompatible dialysate solutions is expected to reshape the market over the forecast period, with manufacturers focusing on neutral pH formulations, low glucose degradation products, improved fluid removal, and patient-friendly PD regimens. The shift toward home dialysis, personalized renal therapy, and better quality-of-life outcomes will remain key growth drivers for non-glucose osmotic agents and advanced PD dialysate solutions.

PESTEL Analysis of the Global Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents And Dialysate Solutions Market

• Political: Government support for home-based dialysis programs is strengthening demand for peritoneal dialysis solutions, especially in countries trying to reduce the pressure on hospital dialysis centers.
• Political: Reimbursement policies, public renal-care funding, and national kidney disease management programs strongly influence the adoption of premium PD dialysate solutions and non-glucose osmotic agents.
• Economic: Rising healthcare expenditure and the growing cost burden of in-center hemodialysis are encouraging payers and providers to consider PD as a cost-effective long-term renal replacement option.
• Economic: Higher product costs, supply-chain dependency, and uneven reimbursement coverage may limit adoption in price-sensitive markets, particularly across low- and middle-income countries.
• Social: Increasing patient preference for home-based treatment, flexible therapy schedules, and improved quality of life is supporting the use of advanced PD solutios.
• Social: The growing elderly population, diabetes-related kidney failure, and rising awareness of chronic kidney disease are expanding the eligible patient base for PD therapies.
• Technological: Development of biocompatible PD fluids, icodextrin-based solutions, amino acid formulations, and emerging non-glucose osmotic agents is improving the clinical value of the market.
• Technological: Integration of automated peritoneal dialysis systems, remote monitoring, and personalized prescription tools is expected to improve treatment adherence and increase demand for specialized dialysate solutions.
• Environmental: Manufacturers are facing growing pressure to reduce plastic waste from PD solution bags, packaging materials, and single-use dialysis consumables.
• Environmental: Sustainable manufacturing, recyclable packaging, and lower carbon footprint distribution models are becoming important considerations for dialysis solution suppliers.
• Legal: Strict regulatory approval requirements, product safety standards, sterility controls, and pharmacovigilance obligations shape market entry and product commercialization.
• Legal: Compliance with medical device, pharmaceutical, and dialysis fluid quality regulations remains critical, as any contamination, labeling error, or supply disruption can directly affect patient safety.

Market Segmentation of the Global Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents And Dialysate Solutions Market

1. By Product / Solution Type
   1.1 Non-Glucose-Based PD Osmotic Agents
   1.2 PD Dialysate Solutions
   1.3 Glucose-Based PD Solutions
   1.4 Icodextrin-Based PD Solutions
   1.5 Polysaccharide-Based Osmotic Drivers
   1.6 Decadextrin-Based PD Osmotic Agents
   1.7 Maltose-Based PD Osmotic Agents
   1.8 Near-Neutral pH PD Solutions
2. By Osmotic Agent Type
   2.1 Glucose-Based Osmotic Agents
   2.2 Non-Glucose Osmotic Agents
   2.3 Icodextrin-Based Osmotic Agents
   2.4 Decadextrin-Based Osmotic Agents
   2.5 Maltose-Based Osmotic Agents
   2.6 Novel Patent-Protected Osmotic Drivers
3. By Dwell Type
   3.1 Short Dwell
   3.2 Long Dwell
   3.3 Day Dwell
   3.4 Night Dwell
4. By Treatment Modality
   4.1 Continuous Ambulatory Peritoneal Dialysis
   4.2 Automated Peritoneal Dialysis
   4.3 Manual Daytime Peritoneal Dialysis
   4.4 Overnight Cycler-Based Peritoneal Dialysis
5. By Clinical Function / Benefit
   5.1 Fluid Elimination / Ultrafiltration
   5.2 Toxin and Waste Clearance
   5.3 Reduced Glucose Absorption
   5.4 Reduced Insulin Response
   5.5 Reduced Weight Gain
   5.6 Reduced Metabolic Stress
   5.7 Peritoneal Membrane Protection
   5.8 Reduced Peritoneal Fibrosis Risk
   5.9 Residual Renal Function Preservation
   5.10 Improved Quality of Life
   5.11 Prolonged PD Treatment Duration
6. By Patient Group
   6.1 Peritoneal Dialysis Patients
   6.2 End-Stage Renal Disease Patients
   6.3 Advanced Chronic Kidney Disease Patients
   6.4 Diabetic PD Patients
   6.5 Non-Diabetic PD Patients
   6.6 PD Patients with Heart Failure
   6.7 Long-Term PD Patients
7. By End-Use Setting
   7.1 Home-Based PD Care
   7.2 Hospitals
   7.3 Dialysis Centers
   7.4 Nephrology Clinics
   7.5 Clinical Trial / Research Settings
8. By Region
   8.1 North America
   8.2 Europe
   8.3 Asia-Pacific
   8.4 Middle East and Africa
   8.5 Latin America

Key Players of the Global Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents And Dialysate Solutions Market

1    Opterion Health
2    Fresenius Medical Care
3    Vantive
4    Mitra Industries
5    WEGO Terumo
6    Zytoprotec
7    Rusoma
8    Iperboreal Pharma Srl
9    Others

Table : Market Snapshot And Strategic Overview – Global Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents And Dialysate Solutions Market

Source: Primary Research and Secondary Research Analysis

Recent Industry Developments In Peritoneal Dialysis Non-Glucose Osmotic Agents And Dialysate Solutions Market

1. Opterion Health Advances First-In-Human Clinical Pathway For Opt101, A Novel Non-Glucose Osmotic Agent For Peritoneal Dialysis

Date: 17 September 2025

Recent Development: Opterion Health AG submitted a Clinical Trial Application to the European Medicines Agency for the first-in-human study of OPT101 in patients with advanced chronic kidney disease on peritoneal dialysis. OPT101 is a novel non-glucose-based osmotic agent designed to address the limitations of glucose-based osmotic agents used in peritoneal dialysis solutions.

Source: Opterion Health AG Press Release

2. Zytoprotec Strengthens Pdprotec Development Through Strategic Collaboration With Shanghai Novasia Medical Technology

Date: February 2026

Recent Development: Zytoprotec signed a term sheet with Shanghai NovAsia Medical Technology Co. to further advance its strategic collaboration. The partnership supports the development of PDprotec, a novel peritoneal dialysis fluid designed to improve PD outcomes, enhance biocompatibility, and reduce treatment burden for kidney failure patients.

Source: Zytoprotec GmbH Company Milestones 

3. Eu-Funded Cordial Project Reports Clinical Validation Of Portable Continuous-Flow Peritoneal Dialysis System With Dialysate Regeneration

Date: 27 February 2026

Recent Development: The European Commission’s CORDIS platform reported positive clinical validation of a portable continuous-flow peritoneal dialysis system with dialysate regeneration. The project aims to improve patient control, home-based therapy convenience, and dialysis efficiency by enabling dialysate regeneration and continuous-flow PD treatment.

Source: European Commission CORDIS 

4. Xylocore Glucose-Sparing Peritoneal Dialysis Solution Gains Clinical Attention Through Elixir Trial Design Publication

Date: 2025

Recent Development: The ELIXIR randomized controlled trial design was published to evaluate the efficacy and safety of XyloCore, a glucose-sparing peritoneal dialysis solution. XyloCore uses osmotic agents such as xylitol and L-carnitine to reduce glucose exposure while supporting ultrafiltration and fluid balance in patients receiving peritoneal dialysis.

Source: Sage Journals

Competitive Product Overview And Solution Portfolio – Global Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents And Dialysate Solutions Market

1. Opterion Health – Opterion ODR / OPT101 Non-Glucose Osmotic Agent For Advanced Peritoneal Dialysis Dialysate Solutions

Opterion Health AG is developing Opterion ODR / OPT101, a novel non-glucose-based osmotic agent for peritoneal dialysis dialysate solutions. The product is designed to support both day and night PD dwells by enabling adaptable ultrafiltration, stable fluid removal, and improved clearance while reducing glucose-related metabolic stress. Its composition, including decadextrin and maltose, is intended to lower glucose exposure, reduce peritoneal membrane deterioration, protect residual renal function, and extend the long-term treatment window for peritoneal dialysis patients.

2. Fresenius Medical Care – Peritoneal Dialysis Fluids And Home Therapy Systems For CAPD And APD Treatment Support

Fresenius Medical Care offers peritoneal dialysis products and therapy systems, including PD fluids such as bicaVera / bicaNova and CAPD support systems such as stay safe balance PD Solution Bag. These products are designed to support fluid inflow and outflow management during peritoneal dialysis, improve handling safety, and assist patients undergoing CAPD or APD therapy. The company is relevant to the PD dialysate solutions market; however, it should not be classified as a confirmed non-glucose osmotic-agent supplier unless product-level validation is available.

3. Vantive – Kidney Care And Home Dialysis Solutions For Peritoneal Dialysis Treatment Expansion

Vantive is a healthcare company focused on vital organ therapies, with a strong legacy in kidney care and dialysis solutions. The company supports patients and clinicians through home dialysis, peritoneal dialysis, digital solutions, advanced services, and education programs designed to improve the overall dialysis experience. In the Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents and Dialysate Solutions Market, Vantive is relevant due to its kidney care expertise, home dialysis support, and commitment to expanding treatment options for chronic kidney disease patients.

4. Mitra Industries – Automated Peritoneal Dialysis Systems, PD Solution Bags, And Home-Based Dialysis Accessories

Mitra Industries provides peritoneal dialysis systems designed to support home-based dialysis for chronic kidney disease patients. Its product portfolio includes the APD m.Cycler automated peritoneal dialysis machine, Tri-Choice Peritoneal Dialysis Solution Bag, Twin Bag, and related PD accessories such as drain bags, transfer sets, clamps, caps, and titanium adapters. These products help patients perform dialysis at home, offering convenience, mobility, and improved quality of life.

5. WEGO Terumo – Neutralized Peritoneal Dialysis Solution For Improved Patient Comfort And Dialysate Compatibility

WEGO Terumo’s neutralized peritoneal dialysis solution is a peritoneal dialysis dialysate developed for patients with chronic kidney failure requiring home-based or routine PD therapy. Approved by China’s NMPA in 2022, the product is designed with a pH closer to human body fluids compared to traditional acidic PD solutions, aiming to improve patient comfort, treatment compatibility, and quality of life. It represents China’s first neutralized peritoneal dialysis solution and supports the growing demand for advanced PD treatment options in the country.

6. Zytoprotec – PDprotec® Next-Generation Peritoneal Dialysis Dialysate For Improved Biocompatibility And Long-Term PD Outcomes

Zytoprotec is developing PDprotec®, a novel peritoneal dialysis dialysate solution designed to improve the safety, efficacy, and long-term outcomes of PD therapy. The product aims to reduce harmful side effects such as peritonitis, protect the peritoneal membrane, support a better inflammatory response, and allow patients to remain on peritoneal dialysis for a longer period. PDprotec® has shown safety and efficacy in Phase 1 and Phase 2 studies and is positioned as a next-generation PD fluid that may improve biocompatibility and patient survival outcomes.

7. Rusoma – Intraperitoneal Dialysis Fluid And PERITON-D Peritoneal Dialysis Solutions For Renal Failure Treatment

Rusoma’s Intraperitoneal Dialysis Fluid and PERITON-D Peritoneal Dialysis Solutions are relevant to the Peritoneal Dialysis Dialysate Solutions segment of the market. These products are dialysis fluids introduced into the peritoneal cavity to help remove toxic substances and excess waste from patients with renal failure. The listed PERITON-D solutions are available in different concentrations and volumes, mainly in plastic containers, supporting peritoneal dialysis treatment. However, the available product information does not clearly show non-glucose osmotic agents, so it should be included under PD dialysate solutions, not specifically under non-glucose osmotic agents.

8. Iperboreal Pharma Srl – XyloCore Glucose-Sparing Peritoneal Dialysis Solution For ESRD Patients On CAPD

Iperboreal Pharma Srl is related to the Peritoneal Dialysis (PD) Non-Glucose Osmotic Agents and Dialysate Solutions Market. The company has a PD project and sponsors clinical development of XyloCore, a glucose-sparing peritoneal dialysis solution designed for ESRD patients on CAPD. XyloCore uses xylitol with reduced glucose and L-carnitine, positioning it as a non- or low-glucose osmotic dialysate alternative aimed at improving PD biocompatibility and reducing glucose exposure during long-term peritoneal dialysis treatment.

9. Others